On Monday, Relay Therapeutics Inc (NASDAQ: RLAY) was 3.39% up from the session before settling in for the closing price of $4.42. A 52-week range for RLAY has been $4.01 – $12.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 399.77% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 9.80%. With a float of $123.37 million, this company’s outstanding shares have now reached $166.89 million.
In an organization with 323 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 58.64%, operating margin of -3926.55%, and the pretax margin is -3449.92%.
Relay Therapeutics Inc (RLAY) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Relay Therapeutics Inc stocks. The insider ownership of Relay Therapeutics Inc is 26.30%, while institutional ownership is 73.17%. The most recent insider transaction that took place on Jan 03 ’25, was worth 138,361. In this transaction an insider of this company sold 32,177 shares at a rate of $4.30, taking the stock ownership to the 325,330 shares. Before that another transaction happened on Jan 02 ’25, when Company’s insider sold 32,156 for $4.15, making the entire transaction worth $133,447. This insider now owns 357,507 shares in total.
Relay Therapeutics Inc (RLAY) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 9.80% per share during the next fiscal year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
You can see what Relay Therapeutics Inc (RLAY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 18.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 78.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.57 in the next quarter and is forecasted to reach -2.64 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.49 million. That was inferior than the volume of 1.49 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 79.44%. Additionally, its Average True Range was 0.29.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 8.35%, which indicates a significant decrease from 55.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.82% in the past 14 days, which was lower than the 92.92% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.00, while its 200-day Moving Average is $6.59. However, in the short run, Relay Therapeutics Inc’s stock first resistance to watch stands at $4.69. Second resistance stands at $4.80. The third major resistance level sits at $4.95. If the price goes on to break the first support level at $4.43, it is likely to go to the next support level at $4.28. Assuming the price breaks the second support level, the third support level stands at $4.17.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
There are 167,383K outstanding shares of the company, which has a market capitalization of 786.28 million. As of now, sales total 25,550 K while income totals -341,970 K. Its latest quarter income was 0 K while its last quarter net income were -92,210 K.
